RDHL - RedHill's Investigational COVID-19 Drugs Combined With Gilead's Show Effect Against Ebola | Benzinga
RedHill Biopharma Ltd (NASDAQ: RDHL) says opaganib and RHB-107 (upamostat) demonstrated robust synergistic effects when combined individually with Gilead Sciences Inc (NASDAQ: GILD) Veklury (remdesivir) in a new U.S. Army-funded and conducted Ebola virus in vitro study.
Preclinical results for opaganib and RHB-107 show a distinct synergy in viral inhibition while maintaining cell viability (i.e., not increasing toxicity).
Twice daily administered opaganib has previously demonstrated benefit in late-stage clinical studies of ...